Heart failure is a common comorbidity of diabetes, particularly in patients with a long duration of diabetes. This week we examine guidelines and data on managing HFrEF and HFpEF, including data from VICTORIA, DAPA-HF and EMPEROR- reduced. Join us to hear Dr Darren McGuire provide his expert opinion on how best to help people with these comorbidities manage both conditions through an optimal treatment pathway.

References:

- Armstrong PW, et al. N Engl J Med. 2020 May 14;382(20):1883-1893.

- Buse JB, et al. Diabetes Care. 2020 Feb;43(2):487-493.

- Gazewood JD, Turner PL. 2017 Nov 1;96(9):582-588. PMID: 29094875.

- McMurray JJV, et al. N Engl J Med. 2019 Nov 21;381(21):1995-2008.

- Murphy SP, Ibrahim NE, Januzzi JL Jr. JAMA. 2020 Aug 4;324(5):488-504.

- Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424.

- Ponikowski P, et al. Eur Heart J. 2016 Jul 14;37(27):2129-2200.

- Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Nat Rev Nephrol. 2016 Oct;12(10):610-23.

- Wallner M, Eaton DM, von Lewinski D, Sourij H. Curr Diab Rep. 2018 Oct 20;18(12):134.

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.